Seymour L, Bezwoda W R
Department of Medicine, University of the Witwatersrand, South Africa.
Br J Cancer. 1993 Aug;68(2):352-6. doi: 10.1038/bjc.1993.339.
The effects of interferon-alpha (IFN) plus tamoxifen (TMX) in the treatment of advanced breast cancer were assessed. Changes of in vivo biologic determinants including hormone receptors, P24 protein, Ki-67 and growth factor expression were evaluated. Seven patients with advanced, heavily pretreated, breast cancer with accessible disease, underwent biopsy prior to and after sequential treatment with IFN and IFN plus TMX. Clinically 4/7 patients responded to treatment with one complete and three partial remissions. Apart from the favourable response rate the sequential in vivo changes in expression of tumour variables were of considerable interest. IFN treatment consistently increased the expression of the estrogen receptor (ER) and of the estrogen regulated protein P24 while decreasing the expression of the proliferation associated antigen Ki-67. Addition of TMX on the other hand resulted in a reduction of ER expression to pre-IFN levels and a rise in progesterone receptor (PR) expression. When the effect of either IFN or IFN plus TMX on the expression of two growth factors was assessed they were found to be somewhat variable. While PDGF expression tended to be suppressed, there was no clinical correlation with response to therapy. TGF beta expression was found in all patients prior to treatment and while all non-responders showed reduction of TGF beta following treatment, the alterations were variable amongst responders (including two patients with increased expression, one with no change, and one with decreased expression). It is concluded that both IFN and TMX exert multiple effects on the expression of tumour biologic variables and that while the study confirmed some of the predictions from in vitro models, the in vivo effect are more complex than has been appreciated from the models. From the clinical point of view, it might be expected that treatment which enhances the expression of ER in tumours should have a positive effect on the response to TMX.
评估了α-干扰素(IFN)联合他莫昔芬(TMX)治疗晚期乳腺癌的效果。评估了包括激素受体、P24蛋白、Ki-67和生长因子表达在内的体内生物学指标的变化。7例晚期、经过大量预处理、病灶可触及的乳腺癌患者,在接受IFN及IFN联合TMX序贯治疗前后进行了活检。临床上,4/7的患者对治疗有反应,1例完全缓解,3例部分缓解。除了良好的缓解率外,肿瘤变量表达的序贯体内变化也颇受关注。IFN治疗持续增加雌激素受体(ER)和雌激素调节蛋白P24的表达,同时降低增殖相关抗原Ki-67的表达。另一方面,添加TMX导致ER表达降至IFN治疗前水平,并使孕激素受体(PR)表达升高。当评估IFN或IFN联合TMX对两种生长因子表达的影响时,发现其变化有些不一致。虽然血小板衍生生长因子(PDGF)表达趋于被抑制,但与治疗反应无临床相关性。所有患者在治疗前均检测到转化生长因子β(TGFβ)表达,所有无反应者在治疗后TGFβ表达均降低,但反应者之间的变化各异(包括2例表达增加、1例无变化和1例表达降低)。结论是,IFN和TMX均对肿瘤生物学变量的表达产生多种影响,虽然该研究证实了体外模型的一些预测,但体内效应比模型中所认识到的更为复杂。从临床角度来看,可以预期增强肿瘤中ER表达的治疗应对TMX的反应产生积极影响。